US FDA declines to approve Capricor's muscle disorder therapy
RefinitivBacaan kurang dari 1 minit
Capricor Therapeutics 
CAPR said on Friday the U.S. Food and Drug Administration has declined to approve its cell therapy for a type of muscle disorder.
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini